Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exeporfinium chloride - Destiny Pharma

Next Previous
Drug Profile

Exeporfinium chloride - Destiny Pharma

Alternative Names: XF 73

Latest Information Update: 27 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Destiny Pharma
  • Developer China Medical System; Destiny Pharma; National Institute of Allergy and Infectious Diseases
  • Class Amines; Anti-inflammatories; Antibacterials; Benzene derivatives; Chlorinated hydrocarbons; Ethers; Porphyrins; Small molecules
  • Mechanism of Action Cell membrane permeability modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Staphylococcal infections
  • Preclinical Bacterial infections; Mucositis; Skin and soft tissue infections
  • No development reported Gram-negative infections; Gram-positive infections

Most Recent Events

  • 28 Aug 2024 Preclinical trials in Staphylococcal infections (Prevention) in USA (Topical, Gel), prior to August 2024
  • 28 Aug 2024 Preclinical trials in Staphylococcal infections in USA (Topical, Gel), prior to August 2024
  • 28 Aug 2024 Exeporfinium chloride receives Qualified Infectious Disease Product status for Staphylococcal infections (Prevention) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top